Nyheter

Läs våra de senaste nyheterna från våra affärsområden
  • 07:46

MatTek and AIM Biotech Partner on Advanced 3D Tissue Culture Organ-on-a-Chip Systems

Share on facebook
Share on twitter
Share on linkedin

Boston, MA – June 1, 2023 – Today, MatTek Life Sciences and AIM Biotech announced a strategic partnership through which the AIM Biotech portfolio will be available for sale through MatTek. Over the last thirty years, MatTek has become the leader in the advanced cell culture space and is continually working to broaden its portfolio of products and services. The partnership with AIM Biotech allows MatTek to provide an ever more comprehensive suite of products and services to its clients and customers.

 

This includes the innovative organiX™ and idenTX™ microfluidic 3D tissue culture platforms as well as comprehensive drug discovery research services in key therapeutic areas of immuno-oncology, vascular biology, and neurobiology.

 

While MatTek has led the field in advanced cell culture and tissue culture for decades with models such as EpiDerm™, and most recently EpiKidney™, these models have been developed as a single organ system within an in vitro format. As researchers push the envelope on advanced in vitro systems, they are becoming more interested in models which incorporate even more physiologically relevant features, such as perfusable vasculature, and even combining multiple organ systems.

 

“One of our goals is to continue to enhance the complexity of in vitro tissue technology and keep bringing it closer and closer to in vivo human biology, and the microfluidic cell culture platforms from AIM Biotech can do just that,” said MatTek CEO Alex Armento. “By partnering with AIM Biotech we can more easily add perfusable vasculature to in vitro models and build ever more physiologically relevant assays which help better predict in vivo outcomes.”

 

“AIM Biotech is excited to partner with MatTek in order to get our advanced 3D tissue culture platforms as well as our extensive portfolio of application-specific guidance and services into the hands of more researchers from around the world. Together we are taking the initiative to combine AIM Biotech’s ability to create self-assembling, immunocompetent, perfusable systems with MatTek’s extensively validated cell culture models. This will enable us to advance the development of assay-ready systems which are easier to use and will provide physiological data earlier in the drug development process,” described AIM Biotech CEO Jim McGorry.

 

AIM Biotech’s Organ-on-a-Chip Tissue Culture Platforms are now available for sale on MatTek’s online store.

 

 

AIM Biotech is a biotechnology company at the forefront of transforming drug discovery into a more targeted, predictable and less expensive endeavor. The company’s patented microfluidic devices and humanized functional assays in critical therapeutic areas enable the addition of human data into drug development earlier in the process, enabling therapeutic insights not previously possible through conventional approaches. AIM Biotech is located in Singapore and Boston, MA.

 

Founded in 1985, MatTek Life Sciences began producing three-dimensional human tissue models as reliable replacements for animal testing. MatTek’s physiologically advanced tissue models empower companies in the cosmetics, chemical, and pharmaceutical industries to achieve their goals of non-animal testing while lowering preclinical costs and providing human-relevant results. With locations in the US and Europe, today MatTek’s offerings include skin, eye, oral, respiratory, vaginal, and intestinal tissue models including disease modeling, validated, and custom testing services, multiple donor primary cells, culture media, and highly optical culture ware.

More news

2024-03-19 | Scienion

sciFLEXARRAYER User Training in Berlin
2023-12-04 | Cellink

Stefan Blomsterberg appointed as new CEO of CELLINK Bioprinting AB 
2023-11-30 | Cellink

CELLINK and Ossiform Enter a Strategic Partnership to launch Ossi Ink, a printable bioink based on Ossiform’s P3D Bone material
2023-11-21 | Cellenion

Cellenion Launches proteoCHIP EVO 96 – Tailored for robust and high-throughput liquid chromatography
2023-11-16 | Scienion

MEDICA 2023: reliable, versatile, and trusted solutions for innovative diagnostics
2023-10-18 | Cellink

CELLINK Announces CELLINK Vivoink: Our First Medical-Grade Bioink 
2023-10-11 | Cellink

CELLINK and the University of California, San Diego Partner to Open a 3D Bioprinting Centre of Excellence 
2023-10-04 | Cellink

Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes
2023-09-28 | Cellink

CELLINK Expands Bioprinting Reach in Portugal and Spain through Strategic Partnership with Paralab
Load more